Pfizer Inc. (pfe)

PFE — Company Overview

Investors tracking PFE follow a Drug Manufacturers - General name listed on NYQ within Healthcare.

PFE — Business Description

The business profile of Pfizer Inc. (PFE) reflects its role in Drug Manufacturers - General. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprisin…

Official website: https://www.pfizer.com.

PFE — Investment Thesis

Pfizer Inc. (PFE) attracts investors weighing Drug Manufacturers - General fundamentals against current market pricing.

• Revenue is expanding at roughly 2.6% year-over-year (public data).
• Trailing P/E of 36.60× implies elevated growth expectations at the current price.
• Forward P/E (9.73×) is below trailing P/E — earnings may be expected to improve.
• Dividend yield near 6.2% adds an income component to total return.
• Equity market capitalization is approximately $160.62B.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

PFE — Financial Health

PFE financial profile reflects operating efficiency and capital structure using available market fundamentals.

Profit margin near 6.8% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $12.49B supports balance-sheet flexibility.

PFE — Growth Outlook

Growth outlook for Pfizer Inc. (PFE) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.

• Revenue growth of 2.6% suggests steady but measured expansion.
• Price is 3.5% below the 52-week high.
• Shares trade 19.5% above the 52-week low — limited rebound so far.

PFE — Competitive Position

Pfizer Inc. (PFE) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

• Competes within Healthcare, specifically in Drug Manufacturers - General.
• Market capitalization of $160.62B places PFE among large-cap peers.
• Gross margin near 74.7% may reflect pricing power or favorable mix.

PFE — Summary

Pfizer Inc. (PFE) is a large-cap Healthcare company focused on Drug Manufacturers - General, listed on NYQ. Last price $28.18 with market cap $160.62B. Trailing P/E 36.60×. Revenue grew 2.6% year-over-year per public data. Notable strengths include gross margin of 74.7% supports competitive unit economics. Key watch items include elevated trailing p/e (36.60×) limits valuation margin of safety. Review free estimates and earnings pages for PFE; upgrade for institutional ownership and live headlines.